Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

Posted by Matt Breese on Dec 11, 2020

Find me on:

According to our recent payer coverage analysis for nonmetastatic prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for nonmetastatic prostate cancer treatments shows that under the pharmacy benefit, almost 58% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Non-Metastatic Prostate Cancer-4Q2020Data snapshot as of Q4 2020

Trends: When the FDA approved Erleada (apalutamide) for the treatment of nonmetastatic castration-resistant prostate cancer on Feb. 14, 2018, it was the first therapy that the agency had approved for that indication. Following the July 30, 2019, approval of Bayer's Nubeqa (darolutamide), three FDA-approved agents, all oral androgen receptor inhibitors, are available to treat the condition, offering a choice of treatment options.  

To read the full Reality Check on Nonmetastatic Prostate Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing